Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma

详细信息    查看全文

• 作者：Ya-Wen Wang (1)
  Duan-Bo Shi (1)
  Ya-Min Liu (1) (2)
  Yan-Lin Sun (1)
  Xu Chen (1)
  Shuai Xiang (1)
  Qiang Fu (1)
  Jun-Min Wei (1) (3)
  Peng Gao (1)
  
• 关键词：Breast carcinoma ; CD227 ; Tumor characteristics ; Invasiveness ; Antisense phosphorothioate oligodeoxynucleotides ; Prognosis
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2014
• 出版时间：August 2014
• 年：2014
• 卷：140
• 期：8
• 页码：1271-1281
• 全文大小：1,990 KB
• 参考文献：1. Acs G, Esposito NN, Rakosy Z, Laronga C, Zhang PJ (2010) Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol 34(11):1637-646. doi:10.1097/PAS.0b013e3181f5539c
  2. Agrawal B, Krantz MJ, Parker J, Longenecker BM (1998) Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res 58(18):4079-081
  3. Angus B, Napier J, Purvis J, Ellis IO, Hawkins RA, Carpenter F, Horne CH (1986) Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11. J Pathol 149(4):301-06. doi:10.1002/path.1711490406 CrossRef
  4. Arnerlov C, Ellis IO, Emdin SO (1988) Monoclonal antibody NCRC 11 reactivity with advanced breast carcinoma: lack of prognostic value. Histopathology 13(6):695-97 CrossRef
  5. Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R, Austrian B, Colorectal Cancer Study G (2001) Evaluation of the United States Food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7(6):1669-675
  6. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50(14):4332-337
  7. Brugger W, Buhring HJ, Grunebach F, Vogel W, Kaul S, Muller R, Brummendorf TH, Ziegler BL, Rappold I, Brossart P, Scheding S, Kanz L (1999) Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 17(5):1535-544
  8. Carraway KL 3rd, Funes M, Workman HC, Sweeney C (2007) Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Topics Develop Biol 78:1-2. doi:10.1016/S0070-2153(06)78001-2 CrossRef
  9. Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1):156-59. doi:10.1006/abio.1987.9999 CrossRef
  10. Cooke T, Reeves J, Lanigan A, Stanton P (2001) HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12(Suppl 1):S23–S28 CrossRef
  11. de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure-ductal carcinoma in situ of the breast. Histopathology 51(2):227-38. doi:10.1111/j.1365-2559.2007.02754.x CrossRef
  12. Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J, Chaganti RS (2000) MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95(8):2666-671
  13. Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076-087
  14. Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, Li H, Shi DB (2013) The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 32(4):491-01. doi:10.1038/onc.2012.61 CrossRef
  15. Hayes DF, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, Wood W, Strauchen JA, Grimes M, Weiss RB et al (1991) Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 9(7):1113-123
  16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clinic 61(2):69-0. doi:10.3322/caac.20107 CrossRef
  17. Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63(16):5011-020
  18. Li YS, Kaneko M, Sakamoto DG, Takeshima Y, Inai K (2006) The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer 13(1):58-3 CrossRef
  19. McGuckin MA (2001) CD227 (MUC1)—summary and workshop report. In: Mason D (ed) Leucocyte typing VII. Oxford University, Oxford, pp 54-6
  20. McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG (1995) Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 26(4):432-39 CrossRef
  21. Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T (1994) MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106(2):353-61
  22. Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay V (2004) Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol 17(9):1045-050. doi:10.1038/modpathol.3800166 CrossRef
  23. Parham DM, Slidders W, Robertson AJ (1988) Quantitation of human milk fat globule (HMFG1) expression in breast carcinoma and its association with survival. J Clin Pathol 41(8):875-79 CrossRef
  24. Rahn JJ, Dabbagh L, Pasdar M, Hugh JC (2001) The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91(11):1973-982 CrossRef
  25. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18(10):1295-304. doi:10.1038/modpathol.3800445 CrossRef
  26. Smith NL, Catrou PG, Payne G, Kellogg AE (2004) Patterns of expression of the DS6-glycoform of MUC1 correlates with known prognostic indicators in breast cancer. In: AACR Meeting Abstracts, 2004. p 239
  27. Suwa T, Hinoda Y, Makiguchi Y, Takahashi T, Itoh F, Adachi M, Hareyama M, Imai K (1998) Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells. Int J Cancer 76(3):377-82 CrossRef
  28. Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC (1999) Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93(4):1287-298
  29. van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 51(3):322-35. doi:10.1111/j.1365-2559.2007.02757.x CrossRef
  30. Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64(11):3780-789. doi:10.1158/0008-5472.CAN-03-1460 CrossRef
  31. Wykes M, MacDonald KP, Tran M, Quin RJ, Xing PX, Gendler SJ, Hart DN, McGuckin MA (2002) MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J Leukocyte Biol 72(4):692-01
  32. Yilmaz M, Christofori G (2010) Mechanisms of motility in metastasizing cells. Mol Cancer Res 8(5):629-42. doi:10.1158/1541-7786.MCR-10-0139 CrossRef
  33. Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8(16):3329-341. doi:10.1002/pmic.200800040 CrossRef
  34. Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S, Kitajima S, Goto M (2011) Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int 61(12):697-16. doi:10.1111/j.1440-1827.2011.02734.x CrossRef
  
• 作者单位：Ya-Wen Wang (1)
  Duan-Bo Shi (1)
  Ya-Min Liu (1) (2)
  Yan-Lin Sun (1)
  Xu Chen (1)
  Shuai Xiang (1)
  Qiang Fu (1)
  Jun-Min Wei (1) (3)
  Peng Gao (1)
  
  1. Department of Pathology, School of Medicine, Shandong University, Wen Hua Xi Road 44, Jinan, 250012, People’s Republic of China
  2. Department of Pathology, Laiwu Steel Affiliated Hospital of Taishan Medical College, Laiwu, People’s Republic of China
  3. Department of Chemotherapy, Qi Lu Hospital, Shandong University, Jinan, People’s Republic of China
  
• ISSN：1432-1335

文摘

Purpose Increasing evidences demonstrate that CD227 plays a crucial role in the development and progression of breast cancer. However, the function of CD227 in breast carcinoma was still controversial and the investigation on CD227 in Asian race was scarce. Methods To investigate the relationship between CD227 and tumor characteristics of breast carcinoma, CD227, estrogen receptor (ER), progesterone receptor (PR), Her2?neu and Ki-67 were detected by immunohistochemistry in a series of 227 patients. The Kaplan–Meier method and log-rank tests were used to estimate the correlation between CD227 expression and patients-prognosis. Furthermore, in vitro invasion assay was performed to examine the effect of CD227 on the invasiveness of breast carcinoma cells after transfection with CD227 cDNA or antisense phosphorothioate oligodeoxynucleotides (ASODN) against CD227 mRNA. Results Our data demonstrate that the cytoplasm staining and high expression of CD227 were positively related to the aggressiveness of breast cancer. Both circumferential membrane staining and cytoplasm staining were associated with lymph node metastasis. Moreover, the cytoplasm staining and overexpression of CD227 were found to be related to Her-2/neu positivity, higher Ki-67 positivity and poorer survival of patients. We further demonstrated that the invasion ability of breast carcinoma cells could be enhanced or inhibited by CD227 cDNA or ASODN, respectively. Conclusions We conclude that the aberrant expression of CD227, especially cytoplasm staining could be predictive for tumor aggressiveness, lymph node metastasis, poorer outcome of patients with breast cancers. And CD227 could promote the invasion ability of breast cancer cells, suggesting a potential role of CD227 as an oncogene in breast carcinoma.